Canaccord Genuity analyst John Young CFA maintained a Hold rating on Staar Surgical yesterday and set a price target of $22.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
John Young CFA has given his Hold rating due to a combination of factors tied to both recent weakness and emerging signs of improvement. He notes that Staar Surgical’s Q4 revenue shortfall and the operational disruption surrounding the terminated Alcon acquisition, along with ongoing uncertainty in China and the absence of formal 2026 guidance, limit near‑term visibility and keep growth expectations below the company’s historical trajectory.
At the same time, he acknowledges a more favorable setup heading into 2026 as new interim leadership outlines a credible plan to restore growth in China, drive share gains in other markets, and preserve the cost reductions achieved in 2025 to support profitable expansion. With EVO ICL remaining a leading, underpenetrated technology and the current valuation offering a cleaner starting point but only moderate implied upside to his $22 price target, he concludes that a Hold rating, rather than a more aggressive stance, is the most balanced recommendation for now.
Young CFA covers the Healthcare sector, focusing on stocks such as Staar Surgical, Merit Medical Systems, and AngioDynamics. According to TipRanks, Young CFA has an average return of -7.3% and a 33.33% success rate on recommended stocks.
In another report released today, Mizuho Securities also maintained a Hold rating on the stock with a $22.00 price target.